Search Results

Arcturus Therapeutics Holdings Inc. today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company’s Board of Directors.

Arcturus Therapeutics Holdings Inc. announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to treat CF, at the 47th European Cystic Fibrosis Conference on June 7, 2024.

Arcturus Therapeutics Holdings Inc. announced that the Company will participate in the following investor and scientific conferences.

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference.

Arcturus Therapeutics Holdings Inc., a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced its financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.

Global biotechnology leader CSL and Arcturus Therapeutics announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying COVID-19 vaccine and the world’s first approved sa-mRNA COVID-19 vaccine.

Arcturus Therapeutics Holdings Inc. today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference.